Clinical Trial Update: Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for the BORID regimen (bortezomib, rituximab, and dexamethasone) in relapsed/refractory mantle cell lymphoma, with the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Decadron (Dexamethasone)
• Rituxan (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: Medical University of Vienna | Conditions: Lymphoma, Mantle-Cell | Phase 2 | Status: UNKNOWN